EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

OncoZenge AB (ONCOZ) fair value: what the stock is really worth

As of Oct 13, 2026: fair value of OncoZenge AB SEK 3.34, price SEK 3.65, upside -8.5%, quality 28 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · SE · ISIN SE0015504097

OA Thin data Oct 14, 2026

OncoZenge AB

ONCOZ · ST

Low PriorityFair Value upside is limited and quality is weak.

The stock costs about what our calculation considers fair.

Fair value kr 3.34 · Fairly valued (−8.5%)
Negative equity (buybacks among others)
Mixed vs. peers (4/7)
Quality 28/100
Weak Growth
Negative free cash flow
Narrow moat 0/100
Thin data
⚠ Dilution
Watch OncoZenge AB for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 14.75 kr 1.69 Fair Value kr 3.34 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 14, 2026.

How to read this chart

60‑month range kr 1.69 – kr 14.75 · fair‑value band kr 2.47 – kr 4.21 · the kr 3.65 price screens above the kr 3.34 fair value. Dashed = 300-day average. As of Oct 14, 2026.

Follow OncoZenge in your weekly email

Every Wednesday you see whether OncoZenge is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

OncoZenge AB (publ), is a clinical-stage pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. The company offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity.

Show more

OncoZenge AB (publ), is a clinical-stage pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. The company offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was founded in 2020 and is headquartered in Bromma, Sweden.

Stock analysis

OncoZenge AB (ONCOZ) currently trades at kr 3.65, while our model-based Fair Value estimate is kr 3.34, so the stock looks roughly fairly valued today (gap 9.2%).

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.

Scenario range: kr 2.47 (bear) to kr 4.21 (bull), the price of kr 3.65 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

OncoZenge AB reported revenue of 2.7M SEK in FY2025 versus 0 SEK in FY2021. Reported net income was −15.9M SEK in FY2025.

Key figures

Market cap 90.2M SEK (≈ $9.1M) · P/S ratio 15.1 · EPS (TTM) kr −1.84 · Return on equity −231% · Return on assets (EBIT) −76.3% · Operating margin −91.3% · Revenue (TTM) 6.0M SEK · Revenue growth (YoY) +50.0%.

What moves the price

The share trades about 56% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −8%, ONCOZ screens richer than that median.

Fair Value models

Bear kr 2.47 Fair Value kr 3.34 Bull kr 4.21
Price kr 3.65 · Upside -8.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EV/EBITDA kr 3.21 kr 4.23 kr 5.25 64
All 1 models by family
Multiples
EV/EBITDA kr 3.21 kr 4.23 kr 5.25 64

Open the full fair value analysis →

Quality Score breakdown

Overall quality 28/100

Of which business quality 28 · Market factors (momentum, volatility) 6

Profitability 1
Margins and returns on capital today
Quality Growth 60
Are margins and returns improving?
Cashflow 7
Earnings quality: real cash, not paper profit
Fin. Strength 45
Balance sheet, leverage, solvency risk
Investment 67
Disciplined investing over empire-building
Low Volatility 17
Calm price path (market factor)
Momentum 0
Price trend over the last 3–12 months (market factor)
52W Momentum 4
Distance to the 52-week high (market factor)
Net Issuance 9
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch ONCOZ, get fair value alerts →

Compare OncoZenge AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 604 stocks

Beats the industry median on 4/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 28 · Bottom 25%
Fair Value upside +7.7% · Top 25%
Profitability
Return on equity (TTM) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −76.2% · Bottom 25%
Operating margin (TTM) −91.3% · Bottom 25%
Growth and dividend
Revenue growth 50.0% · Top 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (TTM) 1.52× · Cheaper than median
EV/EBITDA 0.7× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)22 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 22

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $746.54 $1,275 +71% vs ONCOZ
Vertex Pharmaceuticals Incorporated VRTX $510.08 $561.09 +10% vs ONCOZ
argenx SE ARGX $825.03 $907.53 +10% vs ONCOZ
Samsung Biologics Co 207940 1,219,000 KRW 1,340,900 KRW +10% vs ONCOZ
WuXi Biologics (Cayman) Inc 2269 HK$52.65 HK$57.92 +10% vs ONCOZ
CSL Limited CSL A$181.46 A$179.90 −1% vs ONCOZ
Alnylam Pharmaceuticals, Inc ALNY $232.68 $217.88 −6% vs ONCOZ
BeOne Medicines AG ONC $354.47 $280.94 −21% vs ONCOZ
Celltrion, Inc 068270 180,400 KRW 74,519 KRW −59% vs ONCOZ
Royalty Pharma plc RPRX $56.93 $19.01 −67% vs ONCOZ

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

OncoZenge AB · Fair Value
kr 3.34 −8%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "OncoZenge AB Fair Value". https://www.fairvalue-calculator.com/stock/ONCOZ

Frequently asked questions

Is OncoZenge AB (ONCOZ) overvalued or undervalued?
As of Oct 14, 2026, our model estimates a fair value of kr 3.34 versus a price of kr 3.65, about −8% upside (fairly valued).
What is the fair value of ONCOZ?
Our model-based fair value for OncoZenge AB is kr 3.34 (as of Oct 14, 2026), built from audited fundamentals. The current price: kr 3.65.
What is the quality score of ONCOZ?
OncoZenge AB has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for OncoZenge AB (ONCOZ)?
Our model-based price target is the fair value of kr 3.34 (as of Oct 14, 2026) from 1 valuation models. Cautious scenario kr 2.47, optimistic scenario kr 4.21. It is a calculation from audited fundamentals, not an analyst target.
What is the OncoZenge AB stock forecast for 2026?
Our models put fair value at kr 3.34, about −8% upside versus a price of kr 3.65 (fairly valued). Cautious scenario kr 2.47, optimistic scenario kr 4.21. The calculation is refreshed regularly with new filings.
What is the revenue of OncoZenge AB (ONCOZ)?
OncoZenge AB reported trailing-twelve-month revenue of about 6.0M SEK (latest available figure, as of Oct 14, 2026).
What is the intrinsic value of OncoZenge AB (ONCOZ)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For OncoZenge AB it is kr 3.34 per share (as of Oct 14, 2026), against a price of kr 3.65. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is OncoZenge AB stock overvalued or undervalued in 2026?
As of Oct 14, 2026, ONCOZ trades above its calculated fair value: price kr 3.65, fair value kr 3.34, a gap of about −8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ONCOZ?
No. The price is what the market pays today (kr 3.65); the fair value is what the company's own numbers justify (kr 3.34). For OncoZenge AB the two are kr 0.3090 per share apart. That gap is exactly why we show both numbers side by side.
How much is OncoZenge AB worth?
The market values OncoZenge AB at about 90.2M SEK (market capitalisation, as of Oct 14, 2026). Per share that is kr 3.65; our models calculate a fair value of kr 3.34 per share.
What do the bullish and bearish scenarios say about ONCOZ?
Our models span a range for OncoZenge AB: cautious scenario kr 2.47, base kr 3.34, optimistic kr 4.21 per share (as of Oct 14, 2026, price kr 3.65). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of OncoZenge AB (ONCOZ)?
Balance-sheet figures for OncoZenge AB (as of Oct 14, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 28/100, which measures business quality independently of the share price.
How far is ONCOZ from its 52-week high?
OncoZenge AB trades at kr 3.65, about 56% below its 52-week high of kr 8.36 and 14% above the low of kr 3.20 (as of Oct 13, 2026). Distance from the high says nothing about value: that is what the fair value of kr 3.34 is for.
Which stocks are comparable to OncoZenge AB?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is OncoZenge AB stock attractive at the current price?
The data as of Oct 14, 2026: price kr 3.65, calculated fair value kr 3.34 (−8%), Quality Score 28/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ONCOZ calculated?
We run OncoZenge AB through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 3.34, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. OncoZenge AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of OncoZenge AB (ONCOZ)?
The closing price on Oct 13, 2026 was kr 3.65. Our model-based fair value is kr 3.34, about −8% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with OncoZenge AB right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of OncoZenge AB

How large is the market capitalisation of OncoZenge AB (ONCOZ)?
The market capitalisation of OncoZenge AB is 90.2M SEK (≈ $9.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of OncoZenge AB (ONCOZ)?
The price-to-sales ratio of OncoZenge AB is 15.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of OncoZenge AB (ONCOZ)?
Earnings per share at OncoZenge AB are kr −1.84. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of OncoZenge AB (ONCOZ)?
The return on equity (ROE) of OncoZenge AB is −231% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of OncoZenge AB (ONCOZ)?
On an EBIT basis the return on assets of OncoZenge AB is −76.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of OncoZenge AB (ONCOZ)?
The operating margin of OncoZenge AB is −91.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at OncoZenge AB (ONCOZ)?
Revenue at OncoZenge AB is growing +50.0% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does OncoZenge AB (ONCOZ) generate?
The free cash flow of OncoZenge AB is −13.1M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does OncoZenge AB (ONCOZ) carry?
The net debt of OncoZenge AB is 3.8M SEK (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch OncoZenge AB in the live analysis

One click puts OncoZenge AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.